O
EWTX icon

OrbiMed’s Edgewise Therapeutics EWTX Stock Holding History

OrbiMed’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$489M Hold
15,518,492
– – 9.69% 1
2025
Q4 		$385M Hold
15,518,492
– – 7.86% 1
2025
Q3 		$252M Hold
15,518,492
– – 5.92% 1
2025
Q2 		$203M Buy
15,518,492
+496,771
+3% +$7.16M 5.08% 4
2025
Q1 		$330M Hold
15,021,721
– – 7.88% 2
2024
Q4 		$401M Hold
15,021,721
– – 8.25% 1
2024
Q3 		$401M Hold
15,021,721
– – 7.29% 1
2024
Q2 		$271M Hold
15,021,721
– – 5.34% 3
2024
Q1 		$274M Buy
15,021,721
+454,545
+3% +$7.22M 5.02% 3
2023
Q4 		$159M Hold
14,567,176
– – 3.18% 6
2023
Q3 		$83.5M Hold
14,567,176
– – 1.77% 17
2023
Q2 		$113M Hold
14,567,176
– – 2.05% 11
2023
Q1 		$97.2M Hold
14,567,176
– – 1.91% 14
2022
Q4 		$130M Hold
14,567,176
– – 2.49% 9
2022
Q3 		$143K Buy
14,567,176
+484,496
+3% +$4.9M 2.66% 7
2022
Q2 		$112K Buy
14,082,680
+138,000
+1% +$1.04M 2.03% 13
2022
Q1 		$135M Hold
13,944,680
– – 2.19% 13
2021
Q4 		$213M Hold
13,944,680
– – 2.74% 6
2021
Q3 		$231M Hold
13,944,680
– – 2.54% 9
2021
Q2 		$297M Hold
13,944,680
– – 3.01% 3
2021
Q1 		$453M Buy
+13,944,680
New +$452M 4.24% 2

Other funds holding EWTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed's EWTX Position: Q1 2026 in Review

OrbiMed held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 15,518,492 shares worth $489M. The position accounts for 9.69% of the portfolio, ranked #1.

OrbiMed first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • OrbiMed held 15,518,492 shares of Edgewise Therapeutics worth $489M as of Q1 2026.
  • OrbiMed left its Edgewise Therapeutics share count unchanged in Q1 2026.
  • Edgewise Therapeutics made up 9.69% of OrbiMed's portfolio in Q1 2026, its #1 holding.
  • OrbiMed first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.